These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 9684757

  • 1. Reduced in vitro clot lysis and release of more active platelet PAI-1 in polycythemia vera and essential thrombocythemia.
    Pósán E, Ujj G, Kiss A, Telek B, Rák K, Udvardy M.
    Thromb Res; 1998 Apr 15; 90(2):51-6. PubMed ID: 9684757
    [Abstract] [Full Text] [Related]

  • 2. [Fibrinolysis studied by an in vitro clot lysis test in polycythemia vera].
    Pósán E, Ujj G, Kiss A, Telek B, Rák K, Udvardy M.
    Orv Hetil; 1996 Jan 14; 137(2):71-4. PubMed ID: 8721871
    [Abstract] [Full Text] [Related]

  • 3. Altered plasma fibrin clot properties in essential thrombocythemia.
    Małecki R, Gacka M, Kuliszkiewicz-Janus M, Jakobsche-Policht U, Kwiatkowski J, Adamiec R, Undas A.
    Platelets; 2016 Jan 14; 27(2):110-6. PubMed ID: 25989112
    [Abstract] [Full Text] [Related]

  • 4. Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets.
    Torr-Brown SR, Sobel BE.
    Thromb Res; 1993 Dec 01; 72(5):413-21. PubMed ID: 8303684
    [Abstract] [Full Text] [Related]

  • 5. High plasma levels of plasminogen activator inhibitor 1 (PAI-1) in polycythemia vera and essential thrombocythemia are associated with thrombosis.
    Cancelas JA, García-Avello A, García-Frade LJ.
    Thromb Res; 1994 Sep 01; 75(5):513-20. PubMed ID: 7992252
    [Abstract] [Full Text] [Related]

  • 6. Platelet-related fibrinolysis resistance in patients suffering from PV. Impact of clot retraction and isovolemic erythrocytapheresis.
    Rusak T, Piszcz J, Misztal T, Brańska-Januszewska J, Tomasiak M.
    Thromb Res; 2014 Jul 01; 134(1):192-8. PubMed ID: 24824295
    [Abstract] [Full Text] [Related]

  • 7. The potential role of platelet PAl-1 in t-PA mediated clot lysis of platelet rich plasma.
    Serizawa K, Urano T, Kozima Y, Takada Y, Takada A.
    Thromb Res; 1993 Aug 15; 71(4):289-300. PubMed ID: 8236158
    [Abstract] [Full Text] [Related]

  • 8. Fibrinolytic imbalance in essential thrombocythemia: role of platelets.
    Bazzan M, Tamponi G, Gallo E, Stella S, Schinco PC, Pannocchia A, Pileri A.
    Haemostasis; 1993 Aug 15; 23(1):38-44. PubMed ID: 8477907
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
    Michiels JJ, Berneman Z, Schroyens W, Finazzi G, Budde U, van Vliet HH.
    Semin Thromb Hemost; 2006 Sep 15; 32(6):589-604. PubMed ID: 16977569
    [Abstract] [Full Text] [Related]

  • 12. Markers of endothelial and in vivo platelet activation in patients with essential thrombocythemia and polycythemia vera.
    Karakantza M, Giannakoulas NC, Zikos P, Sakellaropoulos G, Kouraklis A, Aktypi A, Metallinos IC, Theodori E, Zoumbos NC, Maniatis A.
    Int J Hematol; 2004 Apr 15; 79(3):253-9. PubMed ID: 15168594
    [Abstract] [Full Text] [Related]

  • 13. Clot lysis time in platelet-rich plasma: method assessment, comparison with assays in platelet-free and platelet-poor plasmas, and response to tranexamic acid.
    Panes O, Padilla O, Matus V, Sáez CG, Berkovits A, Pereira J, Mezzano D.
    Platelets; 2012 Apr 15; 23(1):36-44. PubMed ID: 21787173
    [Abstract] [Full Text] [Related]

  • 14. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
    Michiels JJ, Berneman Z, Schroyens W, Koudstaal PJ, Lindemans J, Neumann HA, van Vliet HH.
    Platelets; 2006 Dec 15; 17(8):528-44. PubMed ID: 17127481
    [Abstract] [Full Text] [Related]

  • 15. Peroxynitrite may affect fibrinolysis via the reduction of platelet-related fibrinolysis resistance and alteration of clot structure.
    Misztal T, Rusak T, Brańska-Januszewska J, Ostrowska H, Tomasiak M.
    Free Radic Biol Med; 2015 Dec 15; 89():533-47. PubMed ID: 26454084
    [Abstract] [Full Text] [Related]

  • 16. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
    Michiels JJ, Berneman Z, Van Bockstaele D, van der Planken M, De Raeve H, Schroyens W.
    Semin Thromb Hemost; 2006 Apr 15; 32(3):174-207. PubMed ID: 16673274
    [Abstract] [Full Text] [Related]

  • 17. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
    Colucci M, Scopece S, Gelato AV, Dimonte D, Semeraro N.
    Thromb Haemost; 1997 Apr 15; 77(4):725-9. PubMed ID: 9134650
    [Abstract] [Full Text] [Related]

  • 18. The role of platelets and leukocytes in coagulation and fibrinolysis.
    Cucuianu M, Trif I.
    Rev Roum Physiol (1990); 1992 Apr 15; 29(1-2):33-8. PubMed ID: 1472550
    [Abstract] [Full Text] [Related]

  • 19. Increased plasma clot permeability and susceptibility to lysis are associated with heavy menstrual bleeding of unknown cause: a case-control study.
    Szczepaniak P, Zabczyk M, Undas A.
    PLoS One; 2015 Apr 15; 10(4):e0125069. PubMed ID: 25909989
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.